Status:
RECRUITING
Hybrid Effectiveness-Implementation Trial to Integrate Precision Skin Cancer Risk Feedback in FQHCs
Lead Sponsor:
H. Lee Moffitt Cancer Center and Research Institute
Collaborating Sponsors:
National Cancer Institute (NCI)
Conditions:
Skin Cancer
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
The purpose of this study is to examine how different messages about risk of skin cancer can impact the uptake of skin cancer prevention activities.
Eligibility Criteria
Inclusion
- Be a patient of any race or ethnicity attending one of the six Tampa Family Health Centers.
- Be 18 years of age or older.
- Self-report skin cancer risk behaviors within the past 12 months, including: Intentional sun exposure (e.g., outdoor or indoor tanning) or unintentional sun exposure leading to sunburn.
- Be willing to complete a baseline questionnaire and provide a saliva sample for MC1R genotyping.
- Be able to provide informed consent (written or electronic).
- Prefer English or Spanish for communication and study materials.
Exclusion
- Do not report any skin cancer risk behaviors (i.e., no tanning or sunburning in the past 12 months).
- Are unwilling or unable to complete the baseline assessment or return the saliva kit.
- Decline to provide informed consent.
- Are under 18 years of age.
Key Trial Info
Start Date :
October 10 2025
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
October 10 2030
Estimated Enrollment :
2900 Patients enrolled
Trial Details
Trial ID
NCT07222995
Start Date
October 10 2025
End Date
October 10 2030
Last Update
November 3 2025
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Moffitt Cancer Center
Tampa, Florida, United States, 33612
2
Memorial Sloan Kettering Cancer Center
New York, New York, United States, 10065